Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca’s COVID-19 Taskforce Starts With Calquence Trial

BTK Inhibitor Has Shown Results In Advanced COVID-19 Lung Disease

Executive Summary

AstraZeneca will launch a global clinical trial for its blood cancer drug Calquence because it showed early respiratory promise in later-stage COVID-19 patients, those in intensive care units and on ventilators.

You may also be interested in...



NCI Is Being 'Flexible' With COVID-19 Clinical Trial Protocols

At ASCO symposium on cancer care during the pandemic, NCI Director Ned Sharpless notes trial accrual at NCI's National Clinical Trials Network dropped by half in March and April.

AstraZeneca Will Test More Assets Against COVID-19

AstraZeneca, during a strong first-quarter update, underscored its determination to test existing portfolio assets for use in fighting the COVID-19 pandemic.

UK To Speed New COVID-19 Drug Candidates Into Trials

The first of six new compounds are expected to begin Phase II testing soon as part of the UK’s ACCORD initiative, a randomized platform trial bringing together government, industry and research organisations to find potential treatments for COVID-19. 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM004559

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel